Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter single arm study of Bezlotoxumab for prevention of recurrent Clostridium difficile infection

Trial Profile

Multicenter single arm study of Bezlotoxumab for prevention of recurrent Clostridium difficile infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Bezlotoxumab (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2018 New trial record
    • 07 Oct 2018 Results (n=29) assessing Bezlotoxumab treatment for the recurrence of Clostridium difficile Infection, presented at the IDWeek 2018.
    • 07 Oct 2018 Results assessing risk factors for prevention of recurrent clostridium difficle infection, presented at the IDWeek 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top